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Research
Several epidemiologic studies have shown an 
association between lead exposure and cardio-
vascular disease. Recent reports using data 
from the Third National Health and Nutrition 
Examination Survey (NHANES III) suggest 
that even low levels of blood lead (< 10 µg/dL) 
are associated with an increased risk of death 
from all causes and from cardiovascular disease 
(Menke et al. 2006; Schober et al. 2006). A 
review of studies of lead exposure and cardio-
vascular disease concluded that there is suffi-
cient evidence to infer a causal relationship of 
lead exposure with hypertension, and sugges-
tive evidence of a causal relationship between 
lead and clinical cardiovascular outcomes 
and heart rate variability (Navas-Acien et al. 
2007). Because iron can enhance the oxidative 
effects of lead, differences in iron metabolism 
could be a modifier of the adverse effects of 
lead on cardiovascular end points, as has been 
found for other end points (Wang et al. 2007; 
Wright et al. 2004).
Iron is a fundamental nutrient that plays 
a crucial role in vital biochemical activities, 
such as oxygen sensing and transport, elec-
tron transfer, and catalysis (Andrews 2000; 
Papanikolaou and Pantopoulos 2005). Under 
physiologic conditions, iron is bound to 
transferrin, the plasma iron carrier, which 
keeps iron soluble and nontoxic. Free iron 
can react with oxygen through the Fenton 
reaction to form dangerous free radicals that 
damage the macro  molecular components 
of cells (Andrews 2000; Papanikolaou and 
Pantopoulos 2005). Oxidative stress caused 
by excessive free radicals may be associated 
with the pathogenesis of cardio  vascular disease 
(Giordano 2005). Therefore, iron homeo  stasis 
maintained by complex iron-transport and 
management systems is essential to prevent 
oxidative-stress–related health outcomes, and 
genetic polymorphisms affecting these sys-
tems could modify the effects of lead. Three 
specific iron metabolism genes that have 
variants known to alter protein function are 
hemochromatosis (HFE), transferrin (TF), 
and heme oxygenase-1 (HMOX-1). Two mis-
sense mutations of the HFE gene, C282Y and 
H63D, alter iron handling and are related to 
adult-onset hemochromatosis, an autosomal 
recessive genetic disease that increases absorp-
tion of ingested iron (Hanson et al. 2001). 
Transferrin is an iron-binding transport pro-
tein (Namekata et al. 1997b), and the TF C2 
gene variant is a missense polymorphism 
associated with lower iron-binding capacity 
(Wong and Saha 1986). Heme oxygenase-1 
is a heme-degrading enzyme that plays a 
critical role in regulating inflammatory and 
oxidative stress responses to iron (Balla et al. 
2005; Maines 1988). A greater number of GT 
repeats in the HMOX-1 gene promoter may 
reduce heme oxygenase-1 inducibility by reac-
tive oxygen species (Yamada et al. 2000). Long 
alleles of the microsatellite polymorphism in 
HMOX-1 have been associated with respira-
tory (Guenegou et al. 2006; Kikuchi et al. 
2005; Yamada et al. 2000) and cardiovascular 
events (Chen et al. 2002; Funk et al. 2004).
We previously found a significant associa-
tion between cumulative exposure to lead, as 
measured in bone, and prolonged QT interval 
(time from start of the Q wave to end of the 
T wave), a marker of sudden cardiac death 
risk and ventricular arrhythmia, in a commu-
nity-based cohort of elderly men (Cheng et al. 
1998). In the present study, we hypothesized 
that genetic polymorphisms related to iron 
metabolism modify the effect of low-level lead 
exposure on cardiac function. Therefore, we 
examined whether the associations between 
QT interval and lead levels in bone and blood 
are modified by HFE, TF C2, and HMOX-1 
genotypes, and whether there are joint effects 
among these iron metabolism genes.
Materials and Methods
Study population. Participants in our study 
were from the Normative Aging Study (NAS), 
a longitudinal study of aging initiated by the 
Veterans Administration in 1963, when 2,280 
men from the Greater Boston, Massachusetts, 
area free of known chronic medical conditions 
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Ba c k g r o u n d: Cumulative exposure to lead has been shown to be associated with depression of 
electrocardiographic conduction, such as QT interval (time from start of the Q wave to end of 
the T wave). Because iron can enhance the oxidative effects of lead, we examined whether poly-
morphisms in iron metabolism genes [hemochromatosis (HFE), transferrin (TF) C2, and heme 
oxygenase-1 (HMOX­1)] increase susceptibility to the effects of lead on QT interval in 613 commu-
nity-dwelling older men.
Me t h o d s : We used standard 12-lead electrocardiograms, K-shell X-ray fluorescence, and graphite 
furnace atomic absorption spectrometry to measure QT interval, bone lead, and blood lead levels, 
respectively.
re s u l t s: A one-interquartile-range increase in tibia lead level (13 µg/g) was associated with a 
11.35-msec [95% confidence interval (CI), 4.05–18.65 msec] and a 6.81-msec (95% CI, 1.67–11.95 
msec) increase in the heart-rate–corrected QT interval among persons carrying long HMOX­1 
alleles and at least one copy of an HFE variant, respectively, but had no effect in persons with short 
and middle HMOX­1 alleles and the wild-type HFE genotype. The lengthening of the heart-rate–
corrected QT interval with higher tibia lead and blood lead became more pronounced as the total 
number (0 vs. 1 vs. ≥ 2) of gene variants increased (tibia, p-trend = 0.01; blood, p-trend = 0.04). This 
synergy seems to be driven by a joint effect between HFE variant and HMOX­1 L alleles.
co n c l u s i o n: We found evidence that gene variants related to iron metabolism increase the 
impacts of low-level lead exposure on the prolonged QT interval. This is the first such report, so 
these results should be interpreted cautiously and need to be independently verified.
key w o r d s : gene–environment interaction, heme oxygenase-1, hemochromatosis, iron, lead, 
transferrin. Environ Health Perspect 117:80–85 (2009).  doi:10.1289/ehp.11559 available via 
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were enrolled (Bell et al. 1966). Participants 
were asked to return for examinations, includ-
ing electrocardiograms, every 3–5 years. 
Beginning in 1991, NAS participants who 
gave their informed consent were invited to 
undergo bone lead measurements. Blood lead 
was measured in participants’ blood specimens 
obtained during each subject’s visit. Of the 
1,349 subjects who were seen for their regu-
larly scheduled visits between August 1991 
and December 1995, 783 participated in the 
bone lead study. No important differences 
were detected between participants and non-
participants in the bone lead study (Cheng 
et al. 1998). We excluded 8 subjects with high 
bone lead measurement uncertainties (> 10 and 
> 15 µg/g for tibia and patella bones, respec-
tively), 19 subjects missing QT-interval data, 
and 12 subjects with missing values of the 
potential confounding factors. Of the remain-
ing 744 participants, 613 subjects were success-
fully genotyped for all three iron metabolism 
genes, HFE, TF C2, and HMOX-1.
Bone lead and blood lead measurements. 
Bone lead levels were measured using a 
K-shell X-ray fluorescence (KXRF) instrument 
(ABIOMED, Danvers, MA, USA) at two 
sites: the mid  tibial shaft and the patella. The 
physical principles, technical specifications, 
and validation of this instrument have been 
described in detail elsewhere (Burger et al. 
1990). The tibia and patella have been tar-
geted for bone lead research because they con-
sist mainly of pure cortical and pure trabecular 
bone, respectively, and thus represent the two 
main bone compartments. Lead in trabecular 
bone has a faster turnover rate and therefore 
reflects more recent exposure than that in the 
cortical bone. The KXRF instrument provides 
an unbiased estimate of bone lead levels (nor-
malized for bone mineral contents as micro-
grams of lead per gram of bone mineral) and 
an estimate of the uncertainty associated with 
each measurement. Blood lead levels were ana-
lyzed using standard graphite furnace atomic 
absorption spectroscopy. The detection limit 
of this instrument was 1 µg/dL.
QT­interval measurement. Standard rest-
ing 12-lead electrocardiograms taken at the 
same time as subjects’ bone lead and blood 
lead measurements were extracted and sent to 
the Minnesota ECG Coding Center. Tracings 
with any abnormalities were identified and 
classified according to the Minnesota coding 
system. We used the heart-rate–corrected QT 
intervals (QTc), calculated by Bazett’s for-
mula, for analysis.
HFE, TF C2, and HMOX-1 geno­
typing. We extracted high-molecular-weight 
DNA from the white blood cells with com-
mercially available PureGene Kits (Gentra 
Systems, Minneapolis MN, USA). Multiplex 
polymerase chain reaction (PCR) assays were 
designed using SpectroDESIGNER software 
(Sequenom, San Diego, CA, USA) by input-
ting sequence containing the single-nucleotide 
polymorphism (SNP) site and 100 bp of flank-
ing sequence on either side of the SNP. For 
this assay, four SNPs were multiplexed: HFE 
RS1800562 and RS1799945, TF RS1049296, 
and ALAD RS1800435. For this study, we ana-
lyzed only the results for the HFE RS1800562 
and RS1799945 and TF RS1049296 SNPs. 
We carried out multiplex PCR to generate 
short PCR products (> 100 bp) containing 
one SNP or insertion deletion. We used the 
following primers in the multiplex assay: 
a) HFE RS1800562: forward PCR primer 
(5´-ACGTTGGATGTACCCCAGATCA-
CAATGAGG-3´), reverse PCR primer 
(5´-ACGTTGGATGTGGATAACCTT-
GGCTGTACC-3´), extension primer 
(5´-GAAGAGCAGAGATATACGT-3´); 
b) HFE RS1799945: forward PCR primer 
(5´-ACGTTGGATGTCTACTG-
GAAACCCATGGAG-3´), reverse PCR 
primer (5´-ACGTTGGATGTTGAAGC-
TTTGGGCTACGTG-3´), extension primer 
(5´-GCTGTTCGTGTTCTATGAT-3´); 
c) TF RS1049296: forward PCR primer 
(5´-ACGTTGGATGTGAGTT  GC-
TGTGCCTTGATG-3´), reverse PCR primer 
(5´-ACGTTGGATGATCTTTCCGTG-
TGACCACAG-3´), extension primer 
(5´-CGCATACTCCTCCACAG-3´).
The HMOX-1 [UniGene accession number 
Hs.517581 (National Center for Biotechnology 
Information 2008)] micro  satellite (GT)n-length 
assay was designed according to the method of 
Yamada et al. (2000). Briefly, the HMOX-1 
locus was amplified by PCR at the 5´ promoter 
flanking region containing (GT)n repeats 
using a fluorescently labeled sense primer 
(5´-AGAGCCTGCAGCTTCTCAGA-3´) 
and  an  unlabeled  antisense  primer 
(5´-ACAAAGTCTGGCCATAGGAC-3´). 
The sizes of the PCR products were analyzed 
with a laser-based automated DNA sequencer. 
The number of (GT)n repeats in the HMOX-1 
gene promoter ranged from 13 to 41. The 
distribution of (GT)n repeats was trimodal, 
with peaks at 23, 30, and 38 repeats (Figure 1). 
Therefore, we classified the alleles into 
three subclasses according to the number of   
(GT)n repeats, as previously reported 
(Guenegou et al. 2006; Hirai et al. 2003; 
Kikuchi et al. 2005): class S [short, < 27   
(GT)n repeats], class M [medium, 27–32 
(GT)n repeats], and class L [long, ≥ 33 (GT)
n repeats]. The subjects were then classified 
as having L/L, L/M, L/S, M/M, M/S, or 
S/S geno  types. Although the exact cut  off for 
HMOX-1 modulation is still unknown, many 
studies reported that L alleles are associated 
with the development of oxidative-stress–
related diseases (Chen et al. 2002; Guenegou 
et al. 2006; Hirai et al. 2003; Kikuchi et al. 
2005; Yamada et al. 2000).
Statistical analysis. We performed 
allele and genotype frequencies and Hardy-
Weinberg equilibrium tests for each genotype. 
Linear regression analyses were conducted 
to evaluate the association between QTc 
interval and lead biomarkers. We controlled 
for age (years), body mass index (BMI; kg/
m2), smoking status (never/former/current), 
and diabetes status (yes/no). We also con-
trolled for albumin-adjusted serum calcium 
(milligrams per deciliter) because low serum 
calcium was associated with prolonged QTc 
interval among men in NHANES III (Benoit 
et al. 2005). Because lead exposure has been 
associated with hypertension (Hu et al. 1996; 
Navas-Acien et al. 2007) and possibly myo-
cardial infarction (Menke et al. 2006; Schober 
et al. 2006), history of myocardial infarc-
tion and hypertension (yes/no) may be on 
the causal pathway between lead and QTc 
intervals. Therefore, our primary models did 
not contain these variables, but we compared 
these with models that included those vari-
ables. Finally, we compared models with and 
without a variable indicating beta-blocker use 
because they are used for long QT syndrome 
(Shimizu and Antzelevitch 1998), but this 
variable had many missing values.
To assess the potential modifying effects 
of HFE, TF C2, and HMOX-1 genotype, we 
ran separate regression models stratified by 
those genotypes. We also ran regression models 
including a cross-product term for interaction 
between each genotype and each lead marker 
along with the main effects. To evaluate joint 
effects of these three genotypes, we combined 
the three genotypes into a single ordinal vari-
able representing the number of gene variants 
(0 vs. 1 vs. 2 or 3). We also grouped the sub-
jects into the combinations of three genotypes 
(23: none, HFE only, TF C2 only, HMOX-1 
only, HFE and TF C2, TF C2 and HMOX-1, 
HFE and HMOX-1, and all three genotypes) 
and ran separate regression models stratified by 
these categories. To account for chance associa-
tions from multiple comparisons, we estimated 
Figure 1. Distribution of the number of (GT)n 
repeats of the HMOX-1 gene promoter (n = 613; 
1,226 alleles).
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the false-positive report probability (FPRP) 
for statistically significant gene–environment 
interaction findings using a modified method 
described by Wacholder et al. (2004), originally 
introduced in molecular/genetic epidemiology 
and now widely accepted in that literature. 
Although a p-value provides the probability 
of a given test statistic if the null hypothesis 
is true, the FPRP is the probability that an 
observed statistically significant association is a 
false positive. The FPRP value is determined by 
the p-value, the given prior probability for the 
association, and the statistical power of the test. 
We set an FPRP threshold of < 0.5 (i.e., ≤ 50% 
probability that the study hypotheses were 
falsely positive) as “noteworthy” for summary 
interactions; thus, FPRP values < 0.5 indicate 
significant interactions that remained robust 
for a given prior probability. We conducted 
statistical analyses using SAS (version 9.1; SAS 
Institute, Inc., Cary, NC, USA) and R (version 
2.6.1; R Foundation for Statistical Computing 
2003) software systems. All probability values 
are two tailed (α = 0.05).
Results
Table 1 shows the frequencies, bone and 
blood lead levels, and QTc interval by HFE, 
TF C2, and HMOX-1 genotypes. The HFE 
C282Y genotype frequencies were wild type 
(CC), 85.5%; heterozygote (CY), 13.9%; 
and homozygote (YY), 0.7%. Frequencies of 
HFE H63D genotypes were wild type (HH), 
77.2%; heterozygote (HD), 20.2%; and 
homo  zygote (DD), 2.6%. The frequencies 
of TF C2 were C2 negative, 68.7%; hetero-
zygote, 28.2%; and homozygote, 3.1%. 
Seventy-four subjects (12.1%) were L-allele 
(L/L, L/M, L/S) carriers. When collapsed 
into a single variable indicating the presence 
or absence of HFE and TF C2 mutations, 
216 (35.2%) and 192 (31.3%) subjects car-
ried at least one copy of HFE variant and TF 
C2 variants, respectively. The distributions 
of all genotypes were in Hardy-Weinberg 
equilibrium (C282Y: χ2 = 0.07, p = 0.79; TF 
C2: χ2 = 0.46, p = 0.50; HMOX-1: χ2 = 5.59, 
p = 0.13), except H63D (χ2 = 4.88, p = 0.03), 
but the overall prevalence for H63D genotypes 
among those who were genotyped in the NAS 
cohort (n = 1073) was in Hardy-Weinberg 
equilibrium (χ2 = 2.34, p = 0.13). Subjects 
who were homozygous for C282Y had higher 
bone lead levels, and those who were homozy-
gous for H63D and hetero  zygous for both 
C282Y and H63D (compound heterozygotes) 
had lower bone lead levels. There were no dif-
ferences in bone or blood lead levels by TF C2 
or HMOX-1 genotype. QTc intervals did not 
differ by each genotype.
Table 2 presents distributions of charac-
teris  tics for the NAS men in our study sam-
ple (all three genes successfully genotyped; 
n = 613) and those men excluded (missing 
genotype data; n = 131). The men in our study 
sample were slightly younger, had lower tibia 
and patella bone lead levels, and were less likely 
to have a history of myocardial infarction or to 
have ever smoked than those excluded. Among 
those in our study sample, subjects with two or 
three gene variants had slightly lower BMI and 
patella lead levels, and slightly more had never 
smoked, compared with those with zero or one 
gene variant, but otherwise were similar.
We examined the effects of iron metabo-
lism genes on QTc interval independent of lead 
exposures (data not shown). After controlling 
for potential confounders, no iron gene variant 
alone was significantly associated with QTc 
interval. Compared with subjects with no gene 
variants, those with one of any of the three gene 
variants had a borderline significantly lower 
QTc interval [–4.93 msec; 95% confidence 
interval (CI), –10.10 to 0.23 msec], but we 
found no difference in QTc intervals among 
those with two or three gene variants.
In a model including all 613 subjects, 
higher tibia lead and patella lead levels were sig-
nificantly associated with increased QTc inter-
val after adjustment for potential confounders 
(Table 3). Blood lead levels were also positively 
associated with QTc interval, but not signifi-
cantly so. In stratified analyses by HFE, TF C2, 
or HMOX-1 genotypes, the associations of all 
Table 2. Characteristics of study population by the number of gene variants.
  Subjects with  No. of gene variants  Subjects 
Characteristic  all three genotypes  0  1  2 or 3  excludeda
No.  613  237  276  100  131
Continuous variables (mean ± SD)
  Age (years)  67.3 ± 7.2  67.6 ± 7.3  67.3 ± 7.2  66.6 ± 7.0  70.0 ± 7.3
  BMI (kg/m2)  27.9 ± 3.7  28.0 ± 3.8  28.1 ± 3.6  27.2 ± 3.5  27.6 ± 4.5
  Albumin-adjusted serum calcium (mg/dL)  9.0 ± 0.3  9.0 ± 0.3  9.0 ± 0.3  9.0 ± 0.4  9.1 ± 0.4
  Systolic blood pressure (mm Hg)  137.1 ± 18.1  137.0 ± 18.5  136.9 ± 17.1  137.7 ± 20.0  137.0 ± 17.1
  Diastolic blood pressure (mm Hg)  81.7 ± 9.7  81.7 ± 10.0  81.5 ± 9.5  82.4 ± 9.5  80.6 ± 9.5
  QTc interval (msec)  395.7 ± 30.3  398.1 ± 31.7  393.3 ± 28.2  396.5 ± 32.3  400.2 ± 38.7
Categorical variables [n (%)]
  Smoking status
  Never  195 (31.8)  67 (28.3)  92 (33.3)  36 (36.0)  29 (22.1)
  Former  371 (60.5)  151 (63.7)  163 (59.1)  57 (57.0)  91 (69.5)
  Current  47 (7.7)  19 (8.0)  21 (7.6)  7 (7.0)  11 (8.4)
  History of myocardial infarction  29 (4.7)  10 (4.2)  14 (5.1)  5 (5.0)  12 (9.2)
  Diabetes  43 (7.0)  14 (5.9)  22 (8.0)  7 (7.0)  14 (10.7)
  Hypertension  266 (43.4)  108 (45.6)  111 (40.2)  47 (47.0)  53 (40.5)
Lead levels [median (IQR)]
  Tibia lead (µg/g)  19 (14–27)  19 (13–27)  20 (14–28)  19 (12–26)  23 (16–29)
  Patella lead (µg/g)  26 (18–37)  27 (17–39)  26 (18–37)  24 (19–35)  31 (21–43)
  Blood lead (µg/dL)b  5 (4–7)  5 (4–7)  5 (4–7)  5 (3–7)  5 (4–7.5)
QTc intervals = QT measured in lead I × √ (heart rate/60).
aSubjects excluded because of missing genotype data. bReduced numbers of subjects with blood lead for subjects with 
all three genotypes, 0 gene variants, 1 gene variant, and 2 or 3 gene variants were 599, 232, 267, 100, and 128, respectively.
Table 1. Genotype frequencies, bone and blood lead levels, and QTc interval [median (IQR)] by HFE, 
HMOX-1, and TF C2 genotype (n = 613).
    Tibia lead  Patella lead  Blood lead  QTc interval
Genotype  No. (%)  (µg/g)  (µg/g)   (µg/dL)  (msec)
HFE          
  Wild-type (CC/HH)  397 (64.8)  20 (14–28)  27 (18–39)  5 (4–7.5)  394 (376–414)
  C282Y heterozygotes (CY/HH)  72 (11.8)  19.5 (14–26.5)  24.5 (17.5–35.5)  5 (3.7–8)  396 (377–410)
  C282Y homozygotes (YY/HH)  4 (0.7)  35 (29.5–37.5)  42 (28–62)  7.5 (5.5–8)  410 (405–429)
  Compound heterozygotes (CY/HD)  13 (2.1)  15 (9–15)  22 (19–33)  4 (3–5.5)  378 (373–395)
  H63D heterozygotes (CC/HD)  111 (18.1)  19 (14–27)  25 (18–37)  5 (3–7)  393 (374–413)
  H63D homozygotes (CC/DD)  16 (2.6)  17 (12.5–21.5)  24 (18.5–30.5)  5 (4–7)  389 (375–405)
  Presence of either HFE variant   216 (35.2)  19 (14–26)  25 (18–36)  5 (3–7)  393 (376–411)
TF C2          
  Wild-type (–/–)  421 (68.7)  19 (14–27)  27 (18–38)  5 (3.7–7)  394 (377–413)
  C2 heterozygotes (–/+)  173 (28.2)  19 (13–28)  25 (18–36)  5 (3.7–7)  395 (376–410)
  C2 homozygotes (+/+)  19 (3.1)  20 (14–26)  23 (15–40)  5 (4–9)  383 (370–412)
  Presence of TF C2 variant  192 (31.3)  19 (13–27)  24 (17–36)  5 (3.8–8)  394 (374–411)
HMOX-1a       
  S/S  85 (13.9)  20 (13–28)  27 (18–42)  5 (4–7)  394 (376–412)
  M/S  242 (39.5)  19 (14–26)  27 (18–37)  5 (3.7–8)  393 (376–413)
  M/M  212 (34.6)  19.5 (13–27)  24.5 (17–37.5)  5 (3.4–7)  396 (376–413)
  L/S  28 (4.6)  18.5 (13.5–31)  24.5 (19–36)  5 (4–7.5)  387 (371–407)
  L/M  44 (7.2)  19.5 (12.5–27)  24.5 (21–38.5)  5 (3.5–7)  402 (377–413)
  L/L  2 (0.3)  19 (19–19)  33.5 (32–35)  7 (6–8)  362 (334–390)
  Any L allele  74 (12.1)  19 (13–30)  25 (20–36)  5 (4–7)  390 (376–410)
aS, short alleles (< 27 GT repeats) of HMOX-1; M, medium alleles (27–32 GT repeats) of HMOX-1; L, long alleles (≥ 33 GT 
repeats) of HMOX-1.Iron metabolism genes, lead, and QT interval
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lead biomarkers with QTc interval were stron-
ger in persons with gene variants, although the 
interaction by genotype was statistically signifi-
cant only for tibia lead and the HMOX-1 vari-
ants. A one-interquartile-range (IQR) increase 
in tibia lead level (13 µg/g) was associated with 
a 1.60-msec (95% CI, –1.12 to 4.32 msec) 
longer QTc interval among subjects without L 
HMOX-1 alleles and an 11.35-msec (95% CI, 
4.05 to 18.65 msec) longer QTc interval 
among subjects with any L allele, which was 
statistically significantly different (p for inter-
action = 0.01; Table 3). Among subjects with 
either HFE variant, a one-IQR increase in 
tibia lead level was associated with a 6.81-msec 
(95% CI, 1.67 to 11.95 msec) longer QTc 
interval, but although this was a significant and 
much larger effect size than for subjects with 
wild-type HFE, the difference from those with 
wild-type HFE was not statistically significant. 
When we compared individuals with C282Y 
variant (C282Y homozygotes and heterozy-
gotes, n = 89) with those without the C282Y 
variant (i.e., ignoring H63D status; n = 524), 
the difference was borderline significant (p for 
interaction = 0.06; data not shown).
We also found increasing trends in the 
lengthening of the QTc interval with higher 
levels of tibia lead (p-trend = 0.01) and blood 
lead (p-trend = 0.04) as the overall number 
of any of the gene variants increased. Results 
for patella lead were similar but did not reach 
statistical significance.
We calculated FPRP to evaluate whether 
the observed significant interactions between 
tibia lead and both HMOX-1 and the number 
of the gene variants might be false positives 
(data not shown). No FPRP values were less 
than 0.5 even with a high prior probability 
(e.g., prior p = 0.25), indicating that none of 
the significant gene–lead interaction results 
reached the 0.5 FPRP level criterion for being 
noteworthy.
Joint effects between iron metabolism 
geno  types on the association between tibia lead 
levels and QTc interval are shown in Figure 2. 
The association among carriers of HFE alone 
was significantly different from that among 
participants with no variants (p for inter-
action = 0.03). Carriers of HMOX-1 L alleles 
alone had a borderline significant lengthening 
of QTc intervals with increasing tibia lead 
(p for interaction = 0.08). Among carriers of 
both HFE variant and HMOX-1 L alleles, the 
lead-related lengthening of the QTc interval 
(27.64 msec; 95% CI, –4.21 to 59.49 msec; 
n = 19) was substantially longer than the sum 
of the individual associations with either of 
those variants alone, and the effect of tibia 
lead in this group was significantly different 
compared with those with no variants (p for 
interaction = 0.01).
The overall trends with patella lead and 
blood lead were similar to but less significant 
than those with tibia lead (data not shown). 
Further adjustment for hypertension, 
  myo  cardial infarction, and/or beta-blocker 
medication did not change the results (data 
not shown).
Discussion
We found that HFE and HMOX-1 genotypes 
modified the relationship between low-level 
lead exposure, particularly lead in tibia bone, 
and an increase in QTc interval in older men. 
Intriguingly, subjects with both HFE vari-
ants and HMOX-1 L alleles had a particu-
larly large effect estimate for the association 
between tibia lead and QTc interval, sug-
gesting a possible synergy between HFE vari-
ant and HMOX-1 L alleles in modifying the 
association between lead exposure and cardiac 
toxicity. There was less evidence for effect 
modification by TF C2 genotype. Results for 
blood lead were similar to but less significant 
than those for tibia lead.
This is the first study to evaluate effect 
modification by iron metabolism genes either 
individually or jointly on the association 
between low-level lead exposure and prolonged 
QTc interval. Although our study is not a 
comprehensive assessment of iron metabolism 
genes and lead toxicity, it is a logical first step 
in determining whether iron metabolism gene 
variants modify lead toxicity. Each of the gene 
variants we meas  ured increase intra  cellular iron 
(HFE variants), are associated with a disease of 
increased oxidation (TF C2), or are associ-
ated with increased oxidative cellular toxic-
ity (HMOX-1 L alleles). The commonality 
Table 3. Adjusted parameter estimatesa for the difference in QTc interval per IQR increase in lead bio-
marker level, stratified by HFE, TF C2, and HMOX-1 genotypes.
  Tibia lead  Patella lead  Blood lead
  (IQR = 13 µg/g)  (IQR = 19 µg/g)  (IQR = 3 µg/dL)
Parameter  β  95% CI  β  95% CI  β  95% CI
All subjects (n = 613)  2.85  0.29 to 5.40  2.64  0.13 to 5.15  1.30  –0.76 to 3.36
Stratified by iron metabolism genes
  HFE
  Wild type (n = 419)  1.83  –1.17 to 4.83  2.35  –0.63 to 5.33  0.50  –1.89 to 2.89
  HFE variants (n = 228)  6.81  1.67 to 11.95  4.00  –0.97 to 8.97  4.42  –0.06 to 8.91
  p for interactionb  0.11  0.58  0.14
  TF C2         
  C2 negative (n = 443)  1.97  –1.44 to 5.39  1.61  –1.74 to 4.97  0.12  –2.41 to 2.64
  C2 homo/heterozygotes (n = 205)  3.56  –0.32 to 7.44  4.08  0.30 to 7.86  3.27  –0.31 to 6.86
  p for interactionb  0.55  0.35  0.17
  HMOX-1         
  S or M alleles (n = 579)  1.60  –1.12 to 4.32  1.88  –0.83 to 4.59  1.20  –0.96 to 3.36
  Any L allele (n = 83)  11.35  4.05 to 18.65  7.21  0.35 to 14.06  5.09  –1.89 to 12.08
  p for interactionb  0.01  0.14  0.27
  No. of gene variants           
  0 (n = 237)  –2.34  –7.05 to 2.37  –0.53  –5.23 to 4.18  –0.82  –4.35 to 2.71
  1 (n = 276)  5.17  2.02 to 8.32  3.77  0.57 to 6.98  2.65  –0.66 to 5.96
  2 or 3 (n = 100)  7.26  –0.72 to 15.25  5.38  –1.74 to 12.49  6.71  –0.70 to 14.13
  p for trendb  0.01  0.10  0.04
aAdjusted for age, BMI, albumin-adjusted serum calcium, smoking status, and diabetes status. bp-Values for interaction 
and trend between lead biomarker and genotype were computed from the models including cross-product terms between 
genotype and all other covariates analogous to the stratified models.
Figure 2. Adjusted parameter estimates and 95% CIs of QTc interval in relation to an IQR increase in tibia 
lead levels (13 µg/g) stratified by the combinations of HFE, TF C2, and HMOX-1 genotypes. All models were 
adjusted for age, BMI, and smoking status, but non  significant covariates (albumin-adjusted serum calcium 
and diabetes status) used in Table 3 were omitted because the number of subjects with all three variants 
was too small (n = 6) to estimate β-coefficients. The results with and without these covariates were very 
similar in other categories. The numbers next to the upper and lower tails of “All three variants” group 
indicate that the 95% CIs exceed the range of the y-axis.
*p for interaction < 0.05 compared with participants with no variants (None group).
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among these genes of increasing iron-induced 
oxidative toxicity make them of interest not 
only individually but also in combination. 
Interactions between iron metabolism and lead 
toxicity may result from enhanced oxidative 
processes when excess iron and lead co-occur.
The functional defects of the C282Y and 
H63D HFE variant proteins result in iron over-
load (Hanson et al. 2001). In the presence of 
excess iron, exogenous oxidative toxins, such as 
lead, may trigger the Fenton reaction, enhanc-
ing oxidative stress. In fact, lipid peroxi  dation 
by lead is increased in the presence of iron 
(Adonaylo and Oteiza 1999). Therefore, per-
sons with these HFE variants might be expected 
to suffer from an enhanced effect of lead on oxi-
dative-stress–related health outcomes, including 
QTc interval. Lead toxicity affects multiple tis-
sues, and similar oxidative toxicity may occur 
in tissues other than the heart. A recent study 
conducted in the same NAS cohort showed 
that individuals with at least one copy of HFE 
variant had steeper cognitive decline compared 
with wild-type carriers (Wang et al. 2007), 
which supports this hypothesis.
Heme oxygenase-1 is a stress-response pro-
tein that is induced by a variety of oxidative 
stimuli (Maines 1988). Heme oxygenase-1 
lowers levels of free iron in cells, which is an 
important mechanism of its protection against 
oxidative stress. Long alleles of the micro-
satellite polymorphism in HMOX-1 are asso-
ciated with lower protein expression levels 
(Yamada et al. 2000), and therefore higher oxi-
dative stress and related sequelae (Chen et al. 
2002; Funk et al. 2004; Guenegou et al. 2006; 
Kikuchi et al. 2005; Yamada et al. 2000). Lead 
has been found to induce heme oxygenase-1 
both in vitro and in vivo (Cabell et al. 2004; 
Korashy and El-Kadi 2004; Vargas et al. 2003). 
Reduced induction of heme oxygenase-1 by 
lead among subjects with HMOX-1 L alleles 
would result in increased oxidative stress and 
could explain the greater prolongation of the 
QTc interval from lead exposure in this group.
The TF C2 gene product has been associ-
ated with lower total iron-binding capacity 
(Wong and Saha 1986), which has been pro-
posed to lead to excess free iron (Robson et al. 
2004). As in the case of HFE, in the presence 
of excess iron, lead may trigger the Fenton 
reaction and enhance oxidative stress. This 
mechanism has been proposed to explain the 
association between TF C2 and Alzheimer’s 
disease, which involves increased oxidative 
toxicity in the brain (Loeffler et al. 1995; 
Namekata et al. 1997a). It is unclear why car-
rying a TF C2 variant with either HMOX-1 L 
alleles or one of the HFE variants was associ-
ated with a shorter lead-related QTc interval 
increase compared with those with wild-type 
TF and one of the other variants. This could be 
the result of chance, but it raises the possibility 
that the TF C2 variant could be protective for 
the effects of HMOX-1 L alleles or the HFE 
variants on the lead–QTc association.
In our previous study (Cheng et al. 1998), 
the associations between bone lead levels and 
QTc interval were observed only in men 
< 65 years, not in men ≥ 65 years of age. In 
that study, it was proposed that this might 
be due to an increased number of causes of 
cardiac conduction disturbances in the older 
group that may mask the impact of lead expo-
sure. Given those results, an alternative possi-
bility for the present findings could be that the 
observed gene–lead interactions result from an 
unbalanced distribution of genotype by age. 
However, the proportions of those < 65 years 
by genotype [HFE (wild-types, 37.7%, vs. 
variants, 38.6%), TF C2 (wild-types, 36.3%, 
vs. variants, 41.5%), and HMOX-1 (any L 
allele, 41.0%, vs. others, 37.0%)] were very 
similar, and thus the gene–lead interactions we 
report here are likely not simply a proxy for 
age interactions. We could not evaluate two-
way interactions by iron genes and age because 
of the small sample size in each category.
The present study has several limitations. 
We cannot rule out that the observed sig-
nificant interactions may be chance findings 
related to the moderate sample size. Kraft 
and Hunter (2005) indicated that most “sig-
nificant” interactions of gene and environ-
ment will be false positives with sample sizes 
in the order of a few hundred, and our FPRP 
analysis raises concern that this could be the 
case with the present findings. Although our 
study is cross-sectional, because bone lead is 
a marker of long-term cumulative exposures 
to lead, the observed associations would be 
temporally rele  vant. Our study subjects were 
predominantly white men, 95% of whom 
were of European descent, so the present find-
ings may not be generalizable to women or to 
other racial/ethnic groups. On the other hand, 
the homogeneity of our population improves 
internal validity of our results and makes it 
unlikely that population stratification could 
explain our findings. As with all observational 
studies, there is the possibility that residual 
and unmeasured confounding factors may 
have affected our results. We were, however, 
able to account for many known risk factors 
for prolonged QTc interval, such as age, BMI, 
cigarette smoking, serum calcium, and history 
of myocardial infarction, hypertension, and 
diabetes. Therefore, the observed associations 
are unlikely to be explained by these factors. 
Serum iron parameters, such as ferritin and 
transferrin, were not available in this cohort.
In conclusion, our results suggest that 
HMOX-1 L-alleles and C282Y and H63D 
HFE variants—genes involved in iron metabo-
lism—may confer susceptibility to cardiac tox-
icity from lead exposure. They also raise the 
possibility that polymorphisms in iron metabo-
lism genes could also modify susceptibility to 
other factors that can interact with iron to pro-
duce oxidative stress, such as exposure to other 
transition metals. This is the first such report, 
so these results should be interpreted cautiously 
and need to be independently verified.
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